ADAA members receive a complimentary annual online subscription to Depression and Anxiety. With an impact factor of 5.004, this journal ranks 19 of 140 in psychiatry journals and 10 of 76 in psychology journals.
Depression and Anxiety, the official online journal of the Anxiety and Depression Association of America welcomes original research and synthetic review articles covering neurobiology (genetics and neuroimaging), epidemiology, experimental psychopathology, and treatment (psychotherapeutic and pharmacologic) aspects of mood and anxiety disorders, and related phenomena in humans.
A priority is placed on papers focusing on treatment, as well as those providing cutting-edge reviews of key areas and issues, in order to enhance the clinical evaluation and care of individuals struggling with the effects of these disorders. All submissions are peer-reviewed; there is no handling or publishing fee.
NOTE: You must be a current member to log in. Download member log-in instructions here.
If you have questions about your login, please contact ADAA Membership.
Please note: Three open-access journals, the Journal of Depression & Anxiety (OMICS); Anxiety and Depression Research (Herbert Publications); and Annals of Depression and Anxiety (Austin Publishing) are not affiliated with ADAA. These publishers require payment of a handling or submissions fee from authors; find information about these fees on their websites. These publications are not related to Depression and Anxiety, the official ADAA journal.
We invite you to read and share the following early release articles from the March 2017 Journal.
Karen Lynn Cassiday PhD, ACT
Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review
Maria m. Steenkamp PhD, Esther M. Blessing MD PhD, Isaac R. Galatzer-Levy PhD, Laura C. Hollahan MA, William T. Anderson MA
The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis
John Moraros, Chijioke Nwankwo, Scott B. Patten, Darrell D. Mousseau
Beliefs about the causes of depression and recovery and their impact on adherence, dosage, and successful tapering of antidepressants
Nicola S. Klein M.Sc., Gerard D. van Rijsbergen PhD., Mascha C. ten Doesschate MD, PhD, Steven D. Hollon PhD, Huiber Burger MD, PhD, Claudi L.H. Bockting PhD
Internet-based cognitive behavior therapy for major depressive disorder: A randomized controlled trial
Isabelle M. Rosso PhD, William D.S. Killgore PhD, Elizabeth A. Olson, PhD, Christian A. Webb PhD, Rena Fukunaga PhD, Randy P. Auerbach PhD, Hannah Gogel MA, Jennifer L. Buchholz AB, Scott L. Rauch MD
Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year
Aimee R. Kroll-Desrosiers MS, Benjamin C. Nephew PhD, Jessica A. Babb PhD, Yurima Guilarte-Walker M.S., Tiffany A. Moore Simas MD, MPH, MEd., Kristina M. Deligiannidis MD
Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression
Pim Cuijpers, PhD, Erica Weitz, MA, Femke Lamers PhD, Brenda W. Penninx PhD, Jos Twisk PhD, Robert J. DeRubeis PhD, Sona Dimidjian, PhD, Boadie W. Dunlop, MD, MS, Robin B. Jarrett, PhD, Zindel V. Segal, PhD, Steven D. Hollon, PhD
Journal Articles in the News
A Common Medication Given to New Moms Has Been Linked to Postpartum Depression published in GoodHousekeeping (February 10, 2017). Covers "Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year" study by Aimee R. Kroll-Desrosiers MS, Benjamin C. Nephew PhD, Jessica A. Babb PhD, Yurima Guilarte-Walker MS, Tiffany A. Moore Simas MD, MPH, MEd, Kristina M. Deligiannidis MD.